Navigation Links
Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Date:12/19/2011

PALO ALTO, Calif., Dec. 19, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for the first quarter of fiscal year 2012 following the close of regular trading on Wednesday, January 25, 2012.  The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.  The news release and a link to the conference call webcast will be available on the company website at: www.varian.com/investor.  To access the teleconference call and replay:Teleconference:

Access from within the U.S. by dialing 1-866-700-0161, and from outside the U.S. by dialing 1-617-213-8832, and entering code 37675518. 

 Replay:

 

Access from within the U.S. by dialing 1-888-286-8010 and from outside the U.S. by dialing 1-617-801-6888, and entering code 39547714. The teleconference will be rebroadcast until 8:00 p.m. ET, Friday, January 27, 2012. 

 Webcast: 

Visit the company website at: www.varian.com/investor and click on the "Quarterly Conference Call" icon. Web conferences will be archived on the company website for a year.  For automatic "e-mail alerts" regarding Varian news and events, investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.
For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The co
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
2. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
3. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
4. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
5. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
6. OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
7. Prostate cancer risk variant found to be in a functional DNA sequence linked with disease
8. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
9. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... It’s a hard truth: Nearly half of ... their post-secondary education are failing to obtain a diploma or ... And according to an analysis by The Resume Place ... uninformed choice of college majors, which leads to underemployment, unemployment ... Some 51.7 percent of post-9/11 veterans using GI Bill ...
(Date:7/28/2014)... , July 28, 2014   The Atlas ... 4-star boutique hotel in the heart of The Atlas Town Center ... Photo - http://photos.prnewswire.com/prnh/20140725/130455 Photo - ... ATLAS , The Atlas ... suites, a sleek restaurant and bar, a wellness spa, a grand ...
(Date:7/26/2014)... 26, 2014 Canada Endoscopy Visualization ... data on the Canada Endoscopy Visualization Systems market. ... dollars, volume (in units) and average prices (in ... Visualization Systems, Mid-Range Endoscopy Visualization Systems and Low-End ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides ...
(Date:7/25/2014)... CAMBRIDGE, MA -- Trillions of bacteria live in each ... bacteria help digest food and stave off harmful infections, ... understood. , To help shed light on the role ... MIT associate professor Eric Alm recently tracked fluctuations in ... full year. The findings, described in the July 25 ...
Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... SAN DIEGO, Aug. 25 NexBio, Inc. announced today ... Human Lung Tissues" in the September, 2009 issue of the ... DAS181 (Fludase ((R)) ) is an investigational drug ... (e.g. Tamiflu ((R)) ), which target the virus, DAS181 works ...
... 25 Peptimmune, Inc., a privately held biotechnology company, ... the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in ... is a novel peptide copolymer for the treatment of ... The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, ...
... - Medicago Inc. (TSX-V: MDG) a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... from Health Canada to commence a Phase I ... vaccine ("H5N1 vaccine"). Enrollment of volunteers is now ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... have found that targeting a molecule in blood vessels ... research published in Nature today (Sunday)., The ... University of London, have found that a molecule, called ... itself after chemotherapy or radiotherapy, which kill cancer cells ... blood vessels that grew in melanoma or lung cancer ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... the Pediatric Study of Hepatitis C (PEDS-C) trial reveals ... C (HCV) display significant changes in height, weight, body ... the August issue of Hepatology , a journal ... Diseases, indicate that most growth-related side effects are reversible ...
... Clemson University researchers are teaming up with Coastal ... of sensors along the Savannah River to gather data ... will collect and transmit real-time information about the quality ... Intelligent River project leaders Gene Eidson, director of Clemson,s ...
... Lab on a chip (LOC) devicesmicrochip-size systems that can ... from a few microliters (millionth of a liter) to ... to one day revolutionize how laboratory tasks such as ... a recent paper* from the National Institute of Standards ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2NIST focuses on testing standards to support lab on a chip commercialization 2
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
ASCIZ...
...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Biology Products: